Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Late Breaker Abstracts"'
Autor:
Laura Hammitt, Ron Dagan, Yuan Yuan, Manuel Baca Cots, Miroslava Bosheva, Shabhir A Mahdi, William J Muller, Heather J Zar, Dennis Brooks, Amy Grenham, Ulrika Wählby Hamrén, Vaishali S Mankad, Pin Ren, Therese Takas, Jon Heinrichs, Amanda Leach, M Pamela Griffin, Tonya L Villafana
Publikováno v:
Open Forum Infectious Diseases
Background Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in infants. Nirsevimab is a single-dose monoclonal antibody with extended half-life that was shown to protect preterm infants 29 to < 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5de174c6dc7ce4e525e7d3c9e87fc4
http://europepmc.org/articles/PMC8644820
http://europepmc.org/articles/PMC8644820
Autor:
Lauren E Gentles, Leanne P Kehoe, Katharine D Crawford, Kirsten Lacombe, Jane Dickerson, Joanna H Yuan, Susanna L Schuler, Sankan Nyanseor, Sharon Saydah, Claire Midgley, Kimberly Pringle, Jesse Bloom, Janet A Englund
Publikováno v:
Open Forum Infectious Diseases
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits antibodies (Abs) that bind several viral proteins such as the spike entry protein and the abundant nucleocapsid (N) protein. We examined convalescent sera colle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deeebff6cd5a4d0908e73ccf1c91d365
http://europepmc.org/articles/PMC8644934
http://europepmc.org/articles/PMC8644934
Autor:
Teresa H Evering, Mark Giganti, Kara W Chew, Michael Hughes, Carlee Moser, David Alain Wohl, Judith Currier, Joseph J Eron, Arzhang Javan, David A Margolis, Qing Zhu, Ulises D’Andrea, Keila Hoover, Bharat R Mocherla, Courtney Fletcher, Jonathan Li, Davey Smith, Eric Daar
Publikováno v:
Open Forum Infectious Diseases
Open Forum Infectious Diseases, vol 8, iss Supplement_1
Open Forum Infectious Diseases, vol 8, iss Supplement_1
Background SARS-CoV-2 continues to spread and the development of safe and effective therapeutics for the prevention of severe disease remains a priority. BRII-196 and BRII-198 are non-competing anti-SARS-CoV-2 mAbs with YTE triple amino acid substitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d0507720cd0e9e2a47d4560b2b9463f
http://europepmc.org/articles/PMC8644150
http://europepmc.org/articles/PMC8644150
Publikováno v:
Open Forum Infectious Diseases
Background People who use drugs (PWUD) remain at significantly high risk for HIV infection. It is estimated that the majority of all new HIV infections are through injection drug use, with an estimated 2,500 new infections occurring annually among pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::623a726d065370d0d966c004123e9104
http://europepmc.org/articles/PMC8644634
http://europepmc.org/articles/PMC8644634
Autor:
Ely, E Wesley, Ramanan, Athimalaipet V, Kartman, Cynthia E, de Bono, Stephanie, Liao, Ran, Piruzeli, Maria Lucia B, Goldman, Jason D, Saraiva, José Francisco Kerr, Chakladar, Sujatro, Marconi, Vincent
Publikováno v:
Open Forum Infectious Diseases
Background Interventions to reduce mortality in critically ill patients with COVID-19 are a crucial unmet medical need. Baricitinib (BARI) is an oral, selective Janus kinase (JAK)1/JAK2 inhibitor with efficacy in hospitalized adults with COVID-19. Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c0fa25c2881f9d8e34131303c7437ae
https://doi.org/10.1093/ofid/ofab466.1644
https://doi.org/10.1093/ofid/ofab466.1644
Autor:
Mylonakis, Eleftherios, Somersan-Karakaya, Selin, Sivapalasingam, Sumathi, Ali, Shazia, Sun, Yiping, Bhore, Rafia, Mei, Jingning, Miller, Jutta, Cupelli, Lisa, Hooper, Andrea T, Hamilton, Jennifer D, Pan, Cynthia, Pham, Viet, Zhao, Yuming, Hosain, Romana, Mahmood, Adnan, Davis, John D, Turner, Kenneth C, Kim, Yunji, Cook, Amanda, Menon, Vidya, Wells, Jason C, Kowal, Bari, Soo, Yuhwen, DiCioccio, A Thomas, Geba, Gregory P, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary, Yancopoulos, George D, Weinreich, David M
Publikováno v:
Open Forum Infectious Diseases
Background Casirivimab and imdevimab (CAS/IMDEV) is authorized for emergency use in the US for outpatients with COVID-19. We present results from patient cohorts receiving low flow or no supplemental oxygen at baseline from a phase 1/2/3, randomized,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3be1bb679b63ce54642a6b6fd8991ee4
https://doi.org/10.1093/ofid/ofab466.1645
https://doi.org/10.1093/ofid/ofab466.1645
Autor:
Mathieu Le Gars, Jerald Sadoff, Mandy Jongeneelen, Dirk Heerwegh, Georgi Shukarev, Carla Truyers, Anne Marit de Groot, Gert Scheper, Jenny Hendriks, Boerries Brandenburg, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
Publikováno v:
Open Forum Infectious Diseases
Background In a Phase 3 trial, the Janssen COVID-19 vaccine, Ad26.COV2.S, showed robust efficacy against severe–critical COVID-19 in countries where different SARS-CoV-2 variants were circulating. We evaluated Ad26.COV2.S-elicited antibody neutrali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1571a64b6983b2600c1bd2e856c03f99
https://doi.org/10.1093/ofid/ofab466.1638
https://doi.org/10.1093/ofid/ofab466.1638
Autor:
Hill, Joshua A, Paredes, Roger, Vaca, Carlos, Mera, Jorge, Webb, Brandon J, Perez, Gilberto, Oguchi, Godson, Ryan, Pablo, Gerstoft, Jan, Brown, Michael, Schiffer, Joshua, Brown, Samuel, Katz, Morgan, Ginde, Adit A, Camus, Gregory, Porter, Danielle P, Hyland, Robert H, Chen, Shuguang, Juneja, Kavita, Osinusi, Anu, Duff, Frank, Gottlieb, Robert L
Publikováno v:
Open Forum Infectious Diseases
Background Remdesivir (RDV) is a potent nucleotide prodrug inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase that has demonstrated efficacy in the treatment of patients hospitalized with moderate to severe COVID-19. This Phase 3 (GS-US-540–9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57124aba4340510cfbabe4d1183cee90
https://doi.org/10.1093/ofid/ofab466.1642
https://doi.org/10.1093/ofid/ofab466.1642
Publikováno v:
Open Forum Infectious Diseases
Background Given the disproportionate impact of COVID-19 among racial/ethnic minority groups across the United States on emergency visits, hospitalizations, and deaths, we examined healthcare utilization more broadly for acute respiratory illness (AR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3686e94181ebb1f11872ad6daeb00610
https://doi.org/10.1093/ofid/ofab466.1654
https://doi.org/10.1093/ofid/ofab466.1654
Autor:
Dalai, Sudeb C, Greissl, Julia, Pesesky, Mitch, Rebman, Allison W, Soloski, Mark J, Horn, Elizabeth J, Dines, Jennifer N, Gittelman, Rachel M, Snyder, Thomas M, Emerson, Ryan O, Meeds, Edward, Manley, Thomas, Kaplan, Ian M, Baldo, Lance, Carlson, Jonathan M, Robins, Harlan S, Aucott, John
Publikováno v:
Open Forum Infectious Diseases
Background Changing climate and demographic trends have led to recent increases in the incidence of tick-borne illnesses. Early diagnosis of Lyme disease (LD) is critical for initiation of antibiotics to mitigate symptoms and prevent late manifestati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b82c5c06ed2976cec80ded8685cff9e
https://doi.org/10.1093/ofid/ofab466.1653
https://doi.org/10.1093/ofid/ofab466.1653